Stocks News

LAST PRICE
26.5700
TODAY'S CHANGE (%)
Trending Down-1.5700 (-5.5792%)

Bid / Lots
26.5400/ 8
Ask / Lots
26.6000/ 1
Open / Previous Close
28.0000 / 28.1400
Day Range
Low 26.4800
High 28.2000
52 Week Range
Low 4.9600
High 29.5600
Volume
277,033
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 6, 2024
- DJ Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham, from 6:19AM ET on Wednesday Nov 06, 2024 by Dow Jones
  6:19AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 06, 2024 06:19 ET (11:19 GMT)
Nov 5, 2024
- Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting, from 9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
  
  SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that data will be presented from its two Bruton's tyrosine kinase (BTK) degrader programs, NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.
Oct 31, 2024
- Nurix Therapeutics to Participate in Upcoming Investor Conferences, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Nurix Therapeutics to Participate in Upcoming Investor Conferences
  
  SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in November:
Oct 24, 2024
- UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target, from 11:13AM ET on Thursday Oct 24, 2024 by MT Newswires
  11:13AM ET on Thursday Oct 24, 2024 by MT Newswires
  Companies Mentioned: NRIX
  11:13 AM EDT, 10/24/2024 (MT Newswires) -- Nurix Therapeutics (NRIX) has an average outperform rating and price target range of $16 to $41, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from...
- DJ Nurix Therapeutics Initiated at Buy by UBS, from 7:55AM ET on Thursday Oct 24, 2024 by Dow Jones
  7:55AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 24, 2024 07:55 ET (11:55 GMT)

Today
- Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4B7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing, from 7 hours ago by PR Newswire
  7 hours ago by PR Newswire
  Companies Mentioned: SYRE
- Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing, from 7 hours ago by Dow Jones
  7 hours ago by Dow Jones
  Companies Mentioned: SYRE
Yesterday
- Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a4B7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024, from 22 hours ago by PR Newswire
  22 hours ago by PR Newswire
  Companies Mentioned: SYRE
- DJ Intellia Therapeutics Is Maintained at Outperform by Oppenheimer, from 8:31AM ET on Monday Nov 11, 2024 by Dow Jones
  8:31AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: NTLA
- Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating, from 7:37AM ET on Monday Nov 11, 2024 by MT Newswires
  7:37AM ET on Monday Nov 11, 2024 by MT Newswires
  Companies Mentioned: NTLA
Nov 8, 2024
- DJ Intellia Therapeutics Is Maintained at Overweight by Barclays, from 1:16PM ET on Friday Nov 08, 2024 by Dow Jones
  1:16PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: NTLA
Nov 7, 2024
- Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
  4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
  Companies Mentioned: SYRE
- Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SYRE
- Press Release: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SYRE
- DJ Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham, from 7:36AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:36AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RXRX

Nurix Therapeutics Inc
NASDAQ:NRIXUnited States

Search Criteria

Nov 6, 2024

DJ Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham, from 6:19AM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting, from 9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones

Oct 31, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 24, 2024

UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target, from 11:13AM ET on Thursday Oct 24, 2024 by MT Newswires

DJ Nurix Therapeutics Initiated at Buy by UBS, from 7:55AM ET on Thursday Oct 24, 2024 by Dow Jones

Peers Headlines

Today

Yesterday

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a4B7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024, from 22 hours ago by PR Newswire

DJ Intellia Therapeutics Is Maintained at Outperform by Oppenheimer, from 8:31AM ET on Monday Nov 11, 2024 by Dow Jones

Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating, from 7:37AM ET on Monday Nov 11, 2024 by MT Newswires

Nov 8, 2024

DJ Intellia Therapeutics Is Maintained at Overweight by Barclays, from 1:16PM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

Press Release: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham, from 7:36AM ET on Thursday Nov 07, 2024 by Dow Jones